4//SEC Filing
Celator Pharmaceuticals Inc 4
Accession 0001192482-16-000665
CIK 0001327467operating
Filed
Jul 12, 8:00 PM ET
Accepted
Jul 13, 1:06 PM ET
Size
30.7 KB
Accession
0001192482-16-000665
Insider Transaction Report
Form 4
Kollender Richard S
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2016-07-12$27.45/sh−14,000$384,300→ 0 totalExercise: $2.80From: 2016-07-12Exp: 2014-06-12→ Common Stock (14,000 underlying) - Exercise of In-Money
Warrant
2016-06-20−35,737→ 0 total(indirect: By Garden State Life Sciences Venture Fund, L.P.)Exercise: $3.58From: 2013-04-29Exp: 2020-04-29→ Common Stock (35,737 underlying) - Exercise of In-Money
Warrant
2016-06-20−30,708→ 0 total(indirect: By Quaker BioVentures, L.P.)Exercise: $3.58From: 2013-04-29Exp: 2020-04-29→ Common Stock (30,708 underlying) - Exercise of In-Money
Common Stock
2016-06-20+40,614→ 1,327,888 total(indirect: By Quaker BioVentures, L.P.) - Disposition from Tender
Common Stock
2016-07-12$30.25/sh−637,962$19,298,351→ 0 total(indirect: By Garden State Life Sciences Venture Fund, L.P.) - Disposition to Issuer
Stock Option (Right to Buy)
2016-07-12$27.13/sh−28,000$759,752→ 0 totalExercise: $3.12From: 2016-07-12Exp: 2023-06-23→ Common Stock (28,000 underlying) - Exercise of In-Money
Common Stock
2016-06-20+47,265→ 637,962 total(indirect: By Garden State Life Sciences Venture Fund, L.P.) - Disposition from Tender
Common Stock
2016-07-12$30.25/sh−1,327,888$40,168,612→ 0 total(indirect: By Quaker BioVentures, L.P.) - Disposition to Issuer
Warrant
2016-07-12$25.04/sh−12,832$321,284→ 0 total(indirect: By Garden State Life Sciences Venture Fund, L.P.)Exercise: $5.21From: 2012-08-28Exp: 2019-08-28→ Common Stock (12,832 underlying) - Exercise of In-Money
Warrant
2016-06-20−16,391→ 0 total(indirect: By Quaker BioVentures, L.P.)Exercise: $5.21From: 2012-08-28Exp: 2019-08-28→ Common Stock (16,391 underlying) - Exercise of In-Money
Warrant
2016-06-20−19,076→ 0 total(indirect: By Garden State Life Sciences Venture Fund, L.P.)Exercise: $5.21From: 2012-08-28Exp: 2019-08-28→ Common Stock (19,076 underlying) - Disposition to Issuer
Warrant
2016-07-12$25.04/sh−11,027$276,091→ 0 total(indirect: By Quaker BioVentures, L.P.)Exercise: $5.21From: 2012-08-28Exp: 2019-08-28→ Common Stock (11,027 underlying)
Footnotes (5)
- [F1]Includes (i) 27,058 shares of common stock issued upon net exercise of a warrant granted on April 29, 2013 to purchase an aggregate of 30,708 shares of common stock at an exercise price of $3.58 per share; and (ii) 13,556 shares of common stock issued upon net exercise of a warrant granted on August 28, 2012 to purchase an aggregate of 16,391 shares of common stock at an exercise price of $5.2123 per share.
- [F2]Includes (i) 31,489 shares of common stock issued upon net exercise of a warrant granted on April 29, 2013 to purchase an aggregate of 35,737 shares of common stock at an exercise price of $3.58 per share; and (ii) 15,776 shares of common stock issued upon net exercise of a warrant granted on August 28, 2012 to purchase an aggregate of 19,076 shares of common stock at an exercise price of $5.2123 per share.
- [F3]On July 12, 2016, Jazz Pharmaceuticals plc ("Jazz") acquired the issuer pursuant to that certain agreement and plan of merger, dated May 27, 2016 by and among Jazz, Plex Merger Sub, Inc., and the issuer (the "Transaction"). At the effective time of the merger, each outstanding share of the issuer's common stock was converted into the right to receive $30.25 in cash (the "per share merger consideration").
- [F4]In connection with the consummation of the Transaction, each outstanding stock option was exchanged for the right to receive the product of (i) the difference between $30.25 and the exercise price of such option, and (ii) the number of shares subject to such option.
- [F5]In connection with the consummation of the Transaction, and in accordance with this warrant's terms, the warrant was exercised in exchange for consideration equal to the per share merger consideration payable to the warrantholder if the warrant had been exercised in full immediately prior to the consummation of th Transaction.
Documents
Issuer
Celator Pharmaceuticals Inc
CIK 0001327467
Entity typeoperating
Related Parties
1- filerCIK 0001327467
Filing Metadata
- Form type
- 4
- Filed
- Jul 12, 8:00 PM ET
- Accepted
- Jul 13, 1:06 PM ET
- Size
- 30.7 KB